Ⅲ期可手术乳腺癌新辅助化疗的近期和远期效果

Efficacy of the Neoadjuvant Chemotherapy(NACT) for Operable Stage Ⅲ Breast Cancer

目的 探讨Ⅲ期可手术乳腺癌新辅助化疗 (NACT )的效果。方法 将 74例Ⅲ期可手术乳腺癌随机分为A组(NACT组 ,3 6例 )和B组 (对照组 ,3 8例 )。A组采用CAF(CTX/ADM /5 Fu)方案做短期NACT 2个周期 ,随后手术 ,术后辅助放疗、化疗。B组除不行NACT外 ,手术和术后其它治疗与A组相同。结果 A组 (NACT组 )客观有效率为 75 .0 % ,而且A组病理组织学改变较B组明显。 2组 5年生存率和无病生存率 (DFS)分别为 66.7%、3 6.8%和 5 5 .6%、2 6.3 %。A组均高于B组 (P <0 .0 5 )。

Objective To evaluate the efficacy of the neoadjuvant chemotherapy(NACT) for operable stage Ⅲ breast cancer.Methods 74 patients with operable stage Ⅲ breast cancer were randomly assigned to receive either NACT(group A,n=36) or not(group B,n=38).The group A received a short-term NACT with the regiman of CAF(CTX+ADM+5-Fu) for two cycles before operation.The two groups received the same operation and postoperative adjuvant radio-chemotherapy.Results The response rate in group A was 75.0%.The histological changes in group A were more marked than those in group B.The 5-year survival rate(5YSR) and disease-free survivl rate(DFS) were 66.7% and 55.6% for group A,36.8% and 26.3% for group B,respectively,showing a significant difference between the two groups(P<0.05).Conclusion It is suggested that NACT is effective for operable stage Ⅲ breast cancer.